Relypsa raises $80 million for hyperkalaemia drug
This article was originally published in Scrip
Relypsa said on 15 August that it closed an $80 million series C preferred stock financing after it disclosed in a US Securities and Exchange Commission (SEC) filing on 10 August that it raised $49.7 million to begin a Phase III trial this year and a future new drug application (NDA) to the US FDA for patiromer (RLY5016), a high-capacity, non-absorbed oral potassium binder to treat hyperkalaemia in patients with diabetes, chronic kidney disease (CKD) and heart failure (scripintelligence.com, 14 August 2012).
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.